A Aforeworn
Forewarned is forearmed.
Home › Niches › Cosmetics & Personal-Care (MoCRA) › Change
Low urgency

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose

Detected July 6, 2026 · in Cosmetics & Personal-Care (MoCRA)

FDA approved another OTC naloxone nasal spray, but this does not directly affect cosmetics or personal care products under MoCRA.

Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetics and personal care businesses (indie brands, contract manufacturers, private-label makers, importers/distributors) under MoCRA should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA approved Rextovy, an OTC naloxone nasal spray for opioid overdose; no changes to cosmetics regulations.

Who it affects

Cosmetics and personal care businesses (indie brands, contract manufacturers, private-label makers, importers/distributors) under MoCRA

What you must do

No action needed for cosmetics compliance.

Deadline

N/A

Source: http://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose

Never miss a change like this again

Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Cosmetics & Personal-Care (MoCRA)